BCLI Earnings Prediction
The chart below shows how BCLI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BCLI sees a +7.61% change in stock price 10 days leading up to the earnings, and a +6.50% change 10 days following the report. On the earnings day itself, the stock moves by +3.33%. This data can give you a slight idea of what to expect for the next quarter's release.
BCLI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.04
-69.23%
-20.00%
No Data Available
BCLI Earnings Analysis
Brainstorm Cell Therapeutics Inc. Corporation (BCLI.O) Earnings Conference Call
Positive
The company has made substantial progress in preparations for the Phase 3b trial for NurOwn in ALS, with the FDA acknowledging the unmet need in ALS and providing support. The company has also reached alignment with the FDA on critical aspects of the trial, showing progress and commitment to advancing their programs.
Brainstorm is actively pursuing non-dilutive funding, including a grant application with the potential to secure up to $15 million. This strategic approach to funding aims to bolster the company's financial position and accelerate development timelines without significant shareholder dilution.
Financially, the company has shown improvement with cash, cash equivalents, and restricted cash increasing to approximately $3.65 million as of June 30, 2024, compared to $0.75 million in the previous year. Research and development expenses have decreased, indicating efficient capital management.
** Brainstorm Cell Therapeutics has a successful track record of securing non-dilutive funding, such as grants and strategic collaborations, to support its programs. This demonstrates the company's commitment to optimizing capital allocation and maximizing shareholder value without unnecessary dilution.
** The company is actively pursuing multiple non-equity funding sources, including grants, partnerships with pharmaceutical companies, and strategic collaborations. These efforts aim to provide financial support and strategic advantages, contributing to the company's overall development strategy.
Negative
Brainstorm Cell Therapeutics reported a net loss of approximately $2.5 million for the three months ended June 30, 2024, compared to a net loss of approximately $5.3 million for the same period in 2023.
The company's net loss per share for the three months ended June 30, 2024, was $4.13, indicating a negative trend in earnings per share.
General and administrative expenses for the three months ended June 30, 2024, were approximately $2 million, reflecting a decrease from the prior year but still a significant expense.
Cash, cash equivalents, and restricted cash were approximately $3.65 million as of June 30, 2024, compared to $0.75 million as of June 30, 2023, indicating limited financial resources.
Brainstorm Cell Therapeutics is facing challenges with maintaining a $1 share price for 10 consecutive trading days by October 28, 2024, to avoid delisting from NASDAQ.
The company also needs to achieve a $35 million market cap to meet NASDAQ listing requirements.
To address these challenges, Brainstorm Cell Therapeutics is considering a reverse stock split, potentially impacting existing shareholders.
The company's financial position remains a concern, with limited cash on hand and a history of quarterly net losses.
The need for non-dilutive funding sources, such as grants and partnerships, indicates ongoing financial challenges.
The potential dilution of existing shareholders due to the proposed increase in authorized shares raises concerns about future equity raises and shareholder value.
BCLI FAQs
How does BCLI typically perform around its earnings report dates?
Is Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BCLI Earning Call Sentiment
Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Transcript
1.0x
00:00
00:00
BCLI.O
1.48%Positive
The earnings call summary presents a mixed picture. Financial performance shows some improvement, with decreased losses and expenses, but the limited cash position and need for additional funding pose significant risks. The proposed increase in authorized shares and potential reverse stock split to maintain NASDAQ listing could concern shareholders. The Q&A section reveals positive sentiment towards clinical trial adjustments and patient advocacy support, but management's lack of clarity on costs raises uncertainty. Overall, these factors balance each other out, suggesting a neutral stock price movement in the next two weeks.